Adaptive Biotechnologies Corporation
ADPT
Classement en actions
#4133
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Prix de l'action
$24.59
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$3.92B
Changement (1 jour)
2.65%
Changement (1 an)
41.70%
Pays
US
Échange Adaptive Biotechnologies Corporation (ADPT)
Catégorie
Healthcare
Ratio P/E pour Adaptive Biotechnologies Corporation (ADPT)
Ratio P/E au October 2026 TTM : -62.89
Selon les derniers rapports financiers et le cours de l'action de Adaptive Biotechnologies Corporation, le ratio P/E actuel (TTM) est de -62.89. À la fin de l’année 2024, le P/E de l’entreprise était de -5.53.
Historique du ratio P/E pour Adaptive Biotechnologies Corporation de 2017 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | -62.89 | 51.86% |
| 2025 | -41.41 | 648.33% |
| 2024 | -5.53 | 76.19% |
| 2023 | -3.14 | -58.90% |
| 2022 | -7.64 | -60.10% |
| 2021 | -19.15 | -65.53% |
| 2020 | -55.56 | -12.15% |
| 2019 | -63.25 | -30.86% |
| 2018 | -91.48 | -7.79% |
| 2017 | -99.20 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | -145.77% |
US
|
|
| -28.36 | -54.91% |
US
|
|
| -24.57 | -60.93% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -148.23% |
NL
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.